MAXHEALTH was at , during the NSE session on 20 November 2026; its session high was ₹1,090. The story reports Macquarie upgraded both Max Healthcare and Apollo Hospitals to “outperform” and raised its Max target to ₹1,450. That analyst view may support sentiment, but it is not a guarantee—and the live quote is below the story’s cited ₹1,090 level.
Market news
Max Healthcare, Apollo Hospitals shares rally up to 5% as Macquarie double upgrades
Macquarie’s upgrade is a catalyst, but MAXHEALTH still carries a premium valuation
- Price
- ₹1,079.85
- Day change
- +3.77%
- P/E
- 53.79
- ROE
- 21.14%